Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Analysts give Hologic a consensus "Hold": 13 of 15 coverage ratings are holds and 2 are buys, with an average 1‑year price target of about $78.42 and several firms (Argus, Evercore, Weiss) recently downgrading or maintaining hold ratings.
• Hologic's latest quarter came in below estimates, reporting EPS of $1.04 versus a $1.09 consensus and revenue of $1.05B versus $1.07B, though revenue was up 2.5% year‑over‑year.
• Shares trade around $76 with a market cap near $17 billion, a P/E of about 31.7, a 52‑week range of $51.90–$76.07, and roughly 94.7% of the stock held by institutional investors.

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have earned an average recommendation of "Hold" from the fifteen ratings firms that are covering the stock, Marketbeat.com reports. Thirteen analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $78.4167.

A number of analysts have recently commented on the company. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, January 12th. Evercore cut Hologic from an "outperform" rating to an "in-line" rating and reduced their price target for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Hologic in a report on Wednesday, January 28th.

Hedge Funds Weigh In On Hologic

Large investors have recently made changes to their positions in the company. Winnow Wealth LLC acquired a new stake in Hologic during the third quarter valued at $26,000. Root Financial Partners LLC acquired a new position in shares of Hologic in the third quarter worth about $27,000. Harbor Capital Advisors Inc. purchased a new stake in shares of Hologic during the 4th quarter worth about $27,000. SJS Investment Consulting Inc. grew its position in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider's stock valued at $32,000 after acquiring an additional 362 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in shares of Hologic by 168.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider's stock valued at $33,000 after acquiring an additional 310 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

NASDAQ:HOLX opened at $76.01 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The company's fifty day moving average price is $75.37 and its 200-day moving average price is $73.93. Hologic has a 1-year low of $51.90 and a 1-year high of $76.07. The firm has a market capitalization of $16.97 billion, a P/E ratio of 31.67, a PEG ratio of 2.24 and a beta of 0.70.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.87 earnings per share. As a group, equities research analysts anticipate that Hologic will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc NASDAQ: HOLX is a global medical technology company specializing in women's health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.